Leukemia

Bax, Bcl-2, and Bax/Bcl-2 as Prognostic Markers in Acute Myeloid Leukemia: Are We Ready for Bcl-2-Directed Therapy?

Bax, Bcl-2, and Bax/Bcl-2 as Prognostic Markers in Acute Myeloid Leukemia: Are We Ready for Bcl-2-Directed Therapy?

[Cancer Management and Research] This report presents an assessment of the relationship of Bax/Bcl-2 expression and the clinical response of patients with AML treated with cytarabine plus daunorubicin, and their potential as biomarkers to predict chemotherapeutic outcomes.

Elevated Pre-HCT Iron Levels Predictive of Worse Survival Outcomes in AML/MDS

Elevated Pre-HCT Iron Levels Predictive of Worse Survival Outcomes in AML/MDS

By

The ALLIVE trial sought to determine if eLPI levels were predictive of iron-related toxicity and mortality after HCT in patients with AML or MDS.

1-year Imatinib or Nilotinib Therapy Not Associated with Cardiotoxity in CML

1-year Imatinib or Nilotinib Therapy Not Associated with Cardiotoxity in CML

By

Although many TKIs have well-documented cardiotoxic effects, results of a single-center prospective study that assessed effects of 1 year of therapy with imatinib or nilotinib in patients with CML demonstrated safety and efficacy of the 2 agents in this population.

Risk of Secondary Cancers With CML Linked to Disease, Not Treatment

Risk of Secondary Cancers With CML Linked to Disease, Not Treatment

By

This study examined the risk of secondary cancers among patients with CML who were treated with TKIs.

Blinatumomab Indications Expanded to Include MRD+-B-Cell Precursor ALL

Blinatumomab Indications Expanded to Include MRD+-B-Cell Precursor ALL

By

The US FDA approved expanding the indications for the agent to include pediatric and adult patients with B-cell precursor ALL who have minimal residual disease during or after treatment.

Overtreatment a Concern With RAI for Well-Differentiated Thyroid Cancer

Overtreatment a Concern With RAI for Well-Differentiated Thyroid Cancer

By

In a study from the Cleveland Clinic, researchers investigated the association between well-differentiated thyroid cancer and risk for AML or CML in those patients treated with radioactive iodine.

Secondary Outcome Shows Inotuzumab Ozogamicin for B-cell ALL Improves Health-Related QOL

Secondary Outcome Shows Inotuzumab Ozogamicin for B-cell ALL Improves Health-Related QOL

By

Inotuzumab ozogamicin (InO) use may have quality of life benefits for patients with R/R B-cell ALL, as well as producing improved clinical outcomes.

FDA Expands Nilotinib Indication to Include Pediatric Chronic Myeloid Leukemia

FDA Expands Nilotinib Indication to Include Pediatric Chronic Myeloid Leukemia

By

Based on results of 2 prospective studies, the FDA approved the use of nilotinib in pediatric patients older than 1 year with newly diagnosed Ph+ CML-CP and those with TKI-intolerant or resistant disease.

Treatment-Free Remission in Chronic Phase CML Achieved With First-Line Nilotinib

Treatment-Free Remission in Chronic Phase CML Achieved With First-Line Nilotinib

By

Some patients with chronic myeloid leukemia in chronic phase maintained TFR after receiving nilotinib, according to data from the ENESTfreedom study.

Chronic Lymphocytic Leukemia Responds Better to Obinutuzumab Than Other Monoclonal Antibodies

Chronic Lymphocytic Leukemia Responds Better to Obinutuzumab Than Other Monoclonal Antibodies

By

Researchers used mouse cells to determine activation levels of FcγRIIIa and FcγRI using obinutuzumab, rituximab and ofatumumab.

Second-line Nilotinib May Lead to Treatment-Free Remission in Chronic Phase CML

Second-line Nilotinib May Lead to Treatment-Free Remission in Chronic Phase CML

By

Results of the ENESTop study demonstrate the potential for patients with CML who had deep molecular response to achieve long-term treatment-free remission (TFR) after second-line nilotinib, increasing the focus of TFR as a therapeutic outcome.

Monitoring Patients With Chronic Lymphocytic Leukemia  Treated With Venetoclax

Monitoring Patients With Chronic Lymphocytic Leukemia Treated With Venetoclax

By

What are key monitoring guidelines for patients with CLL being treated with venetoclax?

Zinc Sulfate Improves Chemotherapy-Induced Mucositis Outcomes in Leukemia

Zinc Sulfate Improves Chemotherapy-Induced Mucositis Outcomes in Leukemia

By

Results of a triple-blind study demonstrate effectiveness of zinc sulfate in preventing chemotherapy-induced mucositis or reducing its incidence and severity in patients with leukemia receiving chemotherapy.

Treatment-free remission of chronic myeloid leukemia possible after second-line nilotinib

1. Phase 2, open-label study results suggest that treatment-free remission (TFR) of chronic myeloid leukemia (CML) for ≥48 weeks can be reached by over half of patients who have reached deep molecular response (DMR) after ceasing second-line nilotinib treatment. 2. The authors suggest that for patients who do not reach sustained DMR with imatinib, changing []

Tisagenlecleucel Produces Durable Remissions in Pediatric, Young Adult B-cell ALL

Tisagenlecleucel Produces Durable Remissions in Pediatric, Young Adult B-cell ALL

By

A previous single-site trial showed that patients with R/R B-cell ALL treated with tisagenlecleucel achieved high complete remission rates. In this study, investigators report on results after the scope of the study was expanded.

Acute lymphoblastic leukemia disease burden associated with safety and efficacy of CD19-CAR therapy

1. Patients with a higher disease burden of acute lymphoblastic leukemia (ALL) treated with CD19-specific chimeric antigen receptor (CAR) T cell therapy experienced greater incidences of cytotoxic release syndrome and neurotoxicity compared to low disease burden patients. 2. Patients with high disease burden had shorter overall survival times compared to low disease burden patients. Evidence []

Fosfomycin Effective Alternate for Febrile Neutropenia Prophylaxis

Fosfomycin Effective Alternate for Febrile Neutropenia Prophylaxis

By

A retrospective chart study demonstrated the effectiveness of fosfomycin as an antibacterial prophylaxis for febrile neutropenia in patients with hematologic cancer.

2-Year Rituximab Maintenance Therapy Prolongs PFS in Elderly With CLL

2-Year Rituximab Maintenance Therapy Prolongs PFS in Elderly With CLL

By

Investigators sought to determine the efficacy of 2-year rituximab maintenance therapy in elderly patients with CLL who achieve a complete response to abbreviated FCR induction therapy.

Imatinib an Effective Front-line Therapy for Patients With Pediatric CML

Imatinib an Effective Front-line Therapy for Patients With Pediatric CML

By

Patients received imatinib 300 mg/m2, 400 mg/m2, and 500 mg/m2 for chronic phase, accelerated phase, and blast phase disease, respectively.

Venetoclax Effective in Ibrutinib-Failed Chronic Lymphocytic Leukemia

Venetoclax Effective in Ibrutinib-Failed Chronic Lymphocytic Leukemia

By

The efficacy and safety of venetoclax in patients with relapsed/refractory CLL that progressed during or after ibrutinib therapy was determined in an open-label, phase 2 study.

Relapsed Ph-Negative Acute Lymphoblastic Leukemia Incurs a High Economic Burden

Relapsed Ph-Negative Acute Lymphoblastic Leukemia Incurs a High Economic Burden

By

Recent study findings investigated the economic burden of patients with relapsed Ph-negative ALL, and the adverse events of special interest that are most likely to have the greatest impact. These findings were presented at ASH 2017.

Arterial Thrombotic Events Associated With First-line Nilotinib for CML in Older Adults

Arterial Thrombotic Events Associated With First-line Nilotinib for CML in Older Adults

A retrospective analysis of patients with CML determined prevalence of arterial thrombotic events in those receiving nilotinib as first-line treatment and prevalence by patient age. Data were presented at ASH 2017.

More Communication, Support Needed to Manage Symptom Burden in CML

More Communication, Support Needed to Manage Symptom Burden in CML

By

Despite advancements in treatment of CML, many patients still experience adverse effects of their disease and treatments. Therefore, researchers conducted a survey of patients to determine whether they felt assistance and support met their needs.

MDS, AML a Risk With PARP Inhibitors in <i>BRCA</i> Mutation Carriers

MDS, AML a Risk With PARP Inhibitors in BRCA Mutation Carriers

By

What is the concern behind PARP inhibitors and leukemia?

Reduced Delayed Intensification Impacts Risk of Pediatric ALL Relapse

Reduced Delayed Intensification Impacts Risk of Pediatric ALL Relapse

By

Improved survival in pediatric patients with standard-risk ALL has shifted the focus toward reducing treatment burden and toxicity; therefore, researchers sought to determine the effects of reduced DI chemotherapy on relapse and survival.

Dasatinib Granted Regular FDA Approval for Ph+ CML in Pediatric Patients

Dasatinib Granted Regular FDA Approval for Ph+ CML in Pediatric Patients

By

US FDA approval of dasatinib is extended to pediatric patients with Ph+ CML based on data from 2 open-label, nonrandomized trials involving 97 patients.

Oncologists, Patients Have Different Views on AML Treatment Outcomes, Prognosis

Oncologists, Patients Have Different Views on AML Treatment Outcomes, Prognosis

By

Comparison study via questionnaires assessed patients' and oncologists' views on likelihood of dying as a result of treatment shortly after beginning intensive or nonintensive chemotherapy for AML, and their views on prognosis 1 month later.

Neurotoxicity After CAR T-cell Therapy May Be Associated With Endothelial Activation

Neurotoxicity After CAR T-cell Therapy May Be Associated With Endothelial Activation

By

Despite its high response rate, researchers are finding that patients with endothelial activation prior to lymphodepletion chemotherapy are at greater risk of neurologic adverse events after undergoing CAR T-cell therapy for relapsed/refractory B-ALL, CLL, or NHL.

Complications and Management of Coagulation Disorders in Leukemia Patients

Complications and Management of Coagulation Disorders in Leukemia Patients

[Blood and Lymphatic Cancer: Targets and Therapy] Investigators conduct 4 case studies that illustrate a range of coagulation disorders that can develop in patients with leukemia to elucidate the rationale and process of specific treatment options.

Lenalidomide Maintenance Therapy Reduced Risk of Progression in CLL

Lenalidomide Maintenance Therapy Reduced Risk of Progression in CLL

Results of this double-blind, phase 3 study reports on impact of lenalidomide maintenance therapy on risk of disease progression in patients with CLL who did not achieve minimal residual disease state after first-line chemoimmunotherapy.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs